The 22 references in paper O. Koneva A., O. Ovsyannikova B., M. Starovoytova N., O. Desinova V., A. Smirnov V., R. Alekperov T., L. Anan'eva P., О. Конева А., О. Овсянникова Б., М. Старовойтова Н., О. Десинова В., А. Смирнов В., Р. Алекперов Т., Л. Ананьева П. (2017) “Изолированное снижение диффузионной способности легких при системной склеродермии без легочной артериальной гипертензии: длительное проспективное наблюдение // Isolated decrease of the lung diffusing capacity in patients with systemic sclerosis without pulmonary arterial hypertension: a long-term prospective study” / spz:neicon:pulmonology:y:2016:i:6:p:708-714

1
Le Pavec J., Launay D., Mathai S.C. et al. Scleroderma lung disease.Clin. Rev. Allergy Immunol. 2011; 40: 104–116.
(check this in PDF content)
2
Сhang B., Wigley F.M., White B., Wise R.A. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease.J. Rheumatol. 2003; 30: 2398–2405.
(check this in PDF content)
3
Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2011; 34: 1219–1263.
(check this in PDF content)
4
Steen V.D., Conte C., Owens G.R., Medsgar T.A. Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994; 37: 1283–1289. Конева О.А. и др.Изолированное снижение диффузионной способности легких при системной склеродермии
(check this in PDF content)
5
Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972–2002. Ann. Rheum. Dis.2007; 66: 940–944.
(check this in PDF content)
6
Behr J., Furst DE. Pulmonary function test. Rheumatology. 2008; 47: 65–67.
(check this in PDF content)
7
Plummer A.L. The carbon monoxide diffusing capacity: clinical implications, coding, and documentation. Chest. 2008; 134: 663–667.
(check this in PDF content)
8
Steen V.D., Graham G., Conte C. et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum. 1992; 35: 765–770.
(check this in PDF content)
9
Steen V., Medsger T.A. Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003; 48: 516–522.
(check this in PDF content)
10
Mukerjee D., St. Geprge D., Knight C. et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology. 2004; 43: 461–466.
(check this in PDF content)
11
Elhai M., Meune C., Kahan A., Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systemic review and meta-analysis of cohort studies. Rheumatoligy(Oxford). 2012; 51: 1017–1026.
(check this in PDF content)
12
Nichtyanova S.I., Tang E.C., Coghlan J.G. et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM. 2010; 103: 109–115.
(check this in PDF content)
13
Steen V.D., Lucas M., Fertig N., Medsger T.A. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J. Rheumatology.2007; 34: 2230–2235
(check this in PDF content)
14
Trad S., Huong du L.T., Frances C. et al. Impaired carbon monoxide diffusing capacity as a marker of limited systemic sclerosis. Eur. J. Intern. Med. 2011; 22 (6): 80–86. DOI: 10.1016/j.ejim.2011.05.007.
(check this in PDF content)
15
Wells A.U., Hansell D.M., Rubens M.B. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthrit. Rheum.1997; 40 (7): 1229–1236.
(check this in PDF content)
16
Ostojic P., Damjanov N. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin. Rheumatol. 2006; 25 (4): 453–457.
(check this in PDF content)
17
Nyhtyanova S.I., Schreiber B.E., Ong V.H. et al. Prediction of pulmonary complication and long-term survival in systemic sclerosis.Arthrit. Rheum.2014; 66 (6): 1625–1635.
(check this in PDF content)
18
Tashkin D.P., Volkmann E.R., Tseng C.H. et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann. Rheum. Dis.2016; 75 (2): 374–381. DOI: 10.1136/annrheumdis-2014-206076.
(check this in PDF content)
19
Goh N.S., Desai S.R., Veeraraghavan S. et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med.2008; 177 (11): 1248–1254. DOI: 10.1164/rccm.200706-877OC.
(check this in PDF content)
20
Moore O.A., Goh N., Corte T. et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology(Oxford). 2013; 52 (1): 155–160. DOI: 10.1093/rheumatology/kes289.
(check this in PDF content)
21
Hoffmann-Vold A.M., Aalokken T.M., Lund M.B. et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthrit. Rheumatol.2015; 67 (8): 2205–2212. DOI: 10.1002/art.39166.
(check this in PDF content)
22
Winstone T.A., Assayag D., Wilcox P.G. et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014; 146 (2): 422–436. DOI: 10.1378/chest.13-2626. Поступила 13.02.16
(check this in PDF content)